A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease: Probable Benefits of Increasing Folic Acid Intakes

JAMA: The Journal of the American Medical Association

Volumn 274, Issue 13, 1995, Pages 1049-1057

  Boushey, Carol J ^a   Beresford, Shirley A A ^a   Omenn, Gilbert S ^a   Motulsky, Arno G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ARTERIOLOSCLEROSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY RISK; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC VALUE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FOLIC ACID DEFICIENCY; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; VITAMIN INTAKE;

ARTERIOSCLEROSIS; CORONARY DISEASE; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HOMOCYSTEINE; HUMAN; MALE; PYRIDOXINE; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 0029066299     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1995.03530130055028     Document Type: Article

References (107)

1. McCully KS. Vascular pathology of homocysteinemia. Am J Pathol. 1969;56:111-128.
2. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 1976;57:1079-1082.
3. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia. N Engl J Med. 1991;324:1149-1155.
4. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
5. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Arterioscler Thromb. 1993;13:1253-1260.
6. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest. 1988; 81:466-474.
7. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 1988; 48:215-221.
8. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 1994;124:1927-1933.
9. Mereau-Richard C, Muller JP, Faivre E, Ardouin P, Rousseaux J. Total plasma homocysteine determination in subjects with premature cerebral vascular disease. Clin Chem. 1991;37:126.
10. Olszewski AJ. Homocysteine content of plasma in ischemic heart disease, the reducing effect of pyridoxine, folate, cobalamin, choline, riboflavin and troxerutin. Atherosclerosis. 1991;88:97-98.
11. Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in ischemic heart disease. Atherosclerosis. 1988;69:109-113.
12. Olszewski AJ, Szostak WB, Bialkowska M, Rudnicki S, McCully KS. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis. 1989;75:1-6.
13. Andersson A, Isaksson A, Brattstrom L, Israelsson B, Hultberg B. Influence of hydrolysis on plasma homocysteine determination in healthy subjects and patients with myocardial infarction. Atherosclerosis. 1991;88:143-151.
14. Murphy-Chutorian DR, Wexman MP, Grieco AJ, et al. Methionine intolerance. J Am Coll Cardiol. 1985;6:725-730.
15. Kang S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. J Clin Invest. 1986;77:1482-1486.
16. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis. 1988;71:227-233.
17. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice. Coron Artery Dis. 1990;1:215-220.
18. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
19. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr. 1991;69:527-534.
20. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
21. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994;59:940-948.
22. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
23. Graham I. Interactions between homocysteinaemia and conventional risk factors in vascular disease. Eur Heart J. 1994;15(suppl):530.
24. Daly L, Graham I. Hyperhomocysteinaemia: a powerful risk factor for vascular disease. Presented at the Annual Scientific Meeting Working Group/ Epidemiology and Prevention of the European Society of Cardiology; April 25,1994; Venice, Italy.
25. von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994;14:460-464.
26. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism. 1983;32:363-370.
27. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
28. Brattstrom LE, Harbebo JE, Hultberg BL. Moderate homocysteinemia. Stroke. 1984;15:1012-1016.
29. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 1989;79:139-146.
30. Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis. 1990;81:51-60.
31. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 1990;21:572-576.
32. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke. Eur J Clin Invest. 1992;22:214-221.
33. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
34. Malinow MR, Kang S, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with perpherial arterial occlusive disease. Circulation. 1989; 79:1180-1188.
35. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991;13:128-136.
36. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B, Olsson AG. Hyperhomocyst(e)inaemia. J Intern Med. 1992;231:273-279.
37. Bergmark C, Manssor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50: effect of smoking and extent of disease. Eur J Vasc Surg. 1993;7:391-396.
38. Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993;4:295-302.
39. Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism. 1985;34:1073-1077.
40. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994;14:465-470.
41. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47-53.
42. Wilcken DEL, Wilcken B, Dudman NPB, Tyrrell PA. Homocystinuria. N Engl J Med. 1983;309:448-453.
43. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest. 1993;71:993-998.
44. Davis BA, Hofler SA, Bailey LB, O'Keefe CA, Gregory JF, Cerda JJ. Homocysteine response to dietary folate modification in nonpregnant women. FASEB J. 1994;8:A248.
45. Jacob RA, Wu M, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr. 1994;124:1072-1080.
46. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
47. Dean AG, Dean JA, Burton AH, Dicker RC. Epi Info, Version 5: A Word Processing, Database, and Statistics Program for Epidemiology on Microcomputers. Stone Mountain, Ga: USD Inc; 1990.
48. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9: 1-30.
49. Petitti DB. Meta-analysis, Decision-Analysis, and Cost-effectiveness Analysis. New York, NY: Oxford University Press; 1994.
50. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, Mass: Little Brown & Co; 1987.
51. US Bureau of the Census. Statistical Abstract of the United States: 1993. 113th ed. Washington, DC: US Bureau of the Census; 1993.
52. Berg K, Malinow MR, Kierulf P, Upson B. Population variation and genetics of plasma homocyst(e)ine level. Clin Genet. 1992;41:315-321.
53. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine. J Intern Med. 1994;236:633-641.
54. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation. 1993;87:1107-1113.
55. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
56. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med. 1995;332:328-329.
57. den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345:882-885.
58. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
59. Nygard O, Vollset SE, Refsum H, et al. Plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA. In press.
60. Kang S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 1987;36: 458-462.
61. Lewis CA, Pancharuniti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. Ann N Y Acad Sci. 1992;669:360-362.
62. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum. Clin Chem. 1993;39:1764-1779.
63. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60:2-11.
64. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest. 1992;22:79-87.
65. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma. Clin Chem. 1994;40:873-881.
66. Sauberlich HE. Evaluation of folate nutrition in population groups. In: Picciano MF, Stokstad ELR, Gregory JF, eds. Folic Acid Metabolism in Health and Disease. New York, NY: Wiley-Liss; 1990:212-235.
67. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine-β-synthase deficiency. Metabolism. 1988;37:175-178.
68. Lindenbaum J, Healton EB, Sabage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318:1720-1728.
69. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency I. Am J Hematol. 1990;34:90-98.
70. Brattstrom L, Lindgren A. Hyperhomocysteinemia as a risk factor for stroke. Neurol Res. 1992; 14:81-84.
71. Sauberlich HE, Kretsch MJ, Skala JH, Johnson HL, Taylor PC. Folate requirement and metabolism in nonpregnant women. Am J Clin Nutr. 1987;46: 1016-1028.
72. Bender MM, Levy AS, Schucker RE, Yetley EA. Trends in prevalence and magnitude of vitamin and mineral supplement usage and correlation with health status. J Am Diet Assoc. 1992;92:1096-1101.
73. Nightingale SI. Proposals for folic acid fortification and labeling of certain foods to reduce the risk of neural tube defects. JAMA. 1993;270:2283.
74. Federal Register. October 14, 1993;58:53254-53297, 55305-53317.
75. Beresford SAA. How do we get enough folic acid to prevent some neural tube defects? Am J Public Health. 1994;84:348-350.
76. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
77. Willett W. Diet and coronary heart disease. In: Willett W, ed. Nutritional Epidemiology. New York, NY: Oxford University Press; 1990:341-379.
78. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA. 1994;272:1666-1671.
79. Rubba P, Faccenda F, Pauciullo P, et al. Early signs of vascular disease in homocystinuria. Metabolism. 1990;39:1191-1195.
80. Clarke R, Fitzgerald D, O'Brien C, Roche G, Parker RA, Graham I. Hyperhomocysteinaemia. Ir J Med Sci. 1992;161:61-65.
81. Subar AF, Block G, James LD. Folate intake and food sources in the US population. Am J Clin Nutr. 1989;50:508-516.
82. Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency. JAMA. 1993;270:2726-2727.
83. Dudman NPB, Hicks C, Wang J, Wilcken DEL. Human arterial endothelial cell detachment in vitro. Atherosclerosis. 1991;91:77-83.
84. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro. Throm Res. 1980;18:113-121.
85. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis. 1994;94:89-91.
86. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. N Engl J Med. 1974;291:537-543.
87. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. J Clin Invest. 1976;58:731-741.
88. Tsai J, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci US A. 1994;91:6369-6373.
89. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1984;74:1890-1894.
90. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoproteins by arterial smooth muscle cells. J Biol Chem. 1987;262:98-103.
91. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds lead to its recognition by the acetyl LDL receptor. Biochim Biophys Acta. 1987;917:337-350.
92. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991; 88:1906-1914.
93. Reed T, Malinow MR, Christian JC, Upson B. Estimates of heritability of plasma homocyst(e)ine levels in aging adult male twins. Clin Genet. 1991; 39:425-428.
94. Williams RR, Malinow MR, Hunt SC, et al. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coron Artery Dis. 1990;1:681-685.
95. Genest JJ, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991;11:1129-1136.
96. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Inc; 1995:1279-1327.
97. Fenton WA, Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Inc; 1995:3129-3149.
98. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle E, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Inc; 1995:3111-3128.
99. Kang S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia. Am J Hum Genet. 1988;43:414-421.
100. Kang S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase. Am J Hum Genet. 1991;48:536-545.
101. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
102. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease. Nat Genet. 1995;10:111-113.
103. Savage DG, Lindenbaum J. Folate-cobalamin interactions. In: Bailey LB, ed. Folate in Health and Disease. New York, NY: Marcel Dekker Inc; 1995: 237-285.
104. Schafer LW, Larson DE, Melton LT, Higgins JA, Zinsmeister AR. Risk of development of gastric carcinoma in patients with pernicious anemia. Mayo Clin Proc. 1985;60:444-448.
105. Linder MC. Nutrition and metabolism of vitamins. In: Linder MC, ed. Nutritional Biochemistry and Metabolism With Clinical Applications. New York, NY: Elsevier; 1985:69-131.
106. Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992;41:1-7.
107. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.